The Journal of Urology
Volume 182, Issue 5 , Pages 2112-2122 , November 2009

A Framework for the Identification of Men at Increased Risk for Prostate Cancer

  • Monique J. Roobol

      Affiliations

    • Department of Urology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
    • Nothing to disclose.
    • ,
  • Fritz H. Schröder

      Affiliations

    • Department of Urology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
    • Financial interest and/or other relationship with Ferring, GSK, Bayer-Schering, Gen-Probe and Beckman-Coulter.
    • Corresponding Author InformationCorrespondence: Erasmus MC, University Medical Centre, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands (telephone: +31 10 703 4328; FAX: +31 10 703 5315)
    • ,
  • E. David Crawford

      Affiliations

    • Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado
    • Financial interest and/or other relationship with GSK.
    • ,
  • Stephen J. Freedland

      Affiliations

    • Department of Surgery, Durham VA Medical Center and the Departments of Surgery and Pathology, Division of Urologic Surgery, Duke Prostate Center, Duke University Medical Center, Durham, North Carolina
    • Nothing to disclose.
    • ,
  • A. Oliver Sartor

      Affiliations

    • Departments of Medicine and Urology, Tulane Medical School, New Orleans, Louisiana
    • Financial interest and/or other relationship with GSK.
    • ,
  • Neil Fleshner

      Affiliations

    • University Health Network, University of Toronto, Princess Margaret Hospital, Toronto, Ontario, Canada
    • Financial interest and/or other relationship with AstraZeneca, GlaxoSmithKline, Merck, Sanofi-Aventis, Novartis, Pfizer and Bioadvantex Pharma.
    • ,
  • Gerald L. Andriole

      Affiliations

    • Division of Urologic Surgery, Washington University in St. Louis, St. Louis, Missouri
    • Financial interest and/or other relationship with Aeterna Zentaris, Envisioneering, Ferring Pharmaceutical, GlaxoSmithKline, Nema Steba, Onconome, Veridex LLC, Viking Medical Systems and Zeneca.

Received 27 January 2009

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported by GlaxoSmithKline.

 See Editorial on page 2101.

 Editor's Note: This article is the first of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 2538 and 2539.

PII: S0022-5347(09)01742-X

doi: 10.1016/j.juro.2009.07.018

The Journal of Urology
Volume 182, Issue 5 , Pages 2112-2122 , November 2009

Article Tools

* Image Usage & Resolution